MyMD Pharmaceuticals Inc 뉴스 - MYMD | 주식 나스닥 | ADVFN

다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
MyMD Pharmaceuticals Inc (MYMD)
MyMD Pharmaceuticals Inc (MYMD) 뉴스

MyMD Pharmaceuticals Inc (MYMD)

1.82

0.00

(0.00%)

마감 17 2월 6:00AM

0.00

0.00

(0.00%)

시간외 거래: -

개인 투자자를 위한 전문가급 도구.

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc...

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of...

Form 8-K - Current report

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings...

Form D - Notice of Exempt Offering of Securities

Form D - Notice of Exempt Offering of Securities

Form 8-K - Current report

Form 8-K - Current report

MyMD Pharmaceuticals Secures Strategic Investments

Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million...

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

leifsmith

leifsmith 4 주 전

But SeanVan, they have been preparing to advance, and only the need to prepare to prepare has delayed them. Management will soon assure us that they recognize the problem and will soon preparie to prepare to prepare.

SeanVan

SeanVan 5 월 전

$TNFA This company is run by proven track record financial criminals : Jonnie Williams & his slave Josh Silverman...
This is 100% manipulation, they amassed $150M by reducing the price to almost Zero.. $5 to 0.12 cents (30 times reduction) to $3.60 to now $1.50... which means $5 share to 0.05 pennies in value in just 2 years

leifsmith

leifsmith 6 월 전

This Morning: TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

MYMD-1® development to continue through fully funded mid-stage clinical trials

Clinical study of MYMD-1 in sarcopenia/frailty met primary endpoints for significantly reducing chronic inflammatory markers with statistical significance

MYMD-1 shown to inhibit excessive activity of TNF-alpha to regulate the immuno-metabolic system

Company holds FDA-cleared Phase 2 INDs for MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis and Hashimoto’s thyroiditis

Press Release here: https://www.businesswire.com/news/home/20240821460281/en/

"Prepares to advance" — this statement tells us nothing, and the content of the release adds nothing to what is already known.

The new president, Dr. Glass, is quoted as saying, "Our next steps, to be revealed soon, will extend our reach toward significant and sustainable value creation, and long-term Company growth.” <-- If this "to be revealed soon" news is substantial it will prove that today's release was not just an attempt to boost the stock price.

As has been said by critical_perspective we have good reason for skepticism. Today's pre-market action shows that there are some who are taking this release as an opportunity to get out. I hope they will be proven to have misjudged the new management. The science is real and good. What's needed is action. We may be past the point where promises of action will inspire anything.

critical_perspective

critical_perspective 6 월 전

Sorry, Leif, my last post was supposed to be a reply to yours. I also wanted to add that, yes, the reported dramatic improvement in those two dogs is absolutely impressive. Phenomenal, actually! (hopefully it is true). However I still have serious reservations about the company's ownership & leadership. Time will tell.

critical_perspective

critical_perspective 6 월 전

What (if any) science belonging to MYMD might have contributed to the foundation of Telomir? - I, too, wonder about that, especially because the same key individuals are associated with Jonnie Williams in this research and the ever-evolving/re-branding of his corporate projects! Is it revolving doors for them to greener pastures while investors in the 'older projects' are left holding the bag? Dr. Chapman left MyMD to join Telomir Pharma (after previously leaving Rock Creek to join MyMD). He is now deceased and Williams' son-in-law has been brought in to lead Telomir. He also heads Mira Pharma (another Williams production). Notice any patterns?

Which leads me to other questions: Why couldn't they just keep it all under one roof in the same company? Why create new entities?

leifsmith

leifsmith 6 월 전

Telomir Pharmaceuticals was created by former execs and scientists who left MYMD to start it. What (if any) science belonging to MYMD might have contributed to the foundation of Telomir?

From a story published today: "The CEO of Telomir Pharmaceuticals, Dr. Christopher Chapman partnered with Dr. Michael Roizen from the Cleveland Clinic to test a new drug aimed at lengthening telomere caps on human stem cells."

The story: https://www.mysuncoast.com/2024/08/16/abc7-exclusive-new-study-reveals-promising-results-age-reversal-pill-dogs/

The reported rejuvenation of two dogs (not laboratory dogs) is impressive.

Telomir is now able to make some or all of the claims about rejuvenation that justifiably excited investors in MYMD.

leifsmith

leifsmith 6 월 전

The reality is that in the right hands the gains from honest execution could be far greater than the gains from fraud. However, I have no insight into the capabilities, incentives, or moral qualities of the new people.

SeanVan

SeanVan 6 월 전

To wipe out the fraud by previous team Chapman & Kaplin, Jonnie Williams renamed, fired old & hired new.... There is a fraud in veery step.

leifsmith

leifsmith 7 월 전

https://tnfpharma.com/about-us

FALCON1

FALCON1 7 월 전

https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation

Lime Time

Lime Time 7 월 전

MYMD to TNFA, 7/24/2024:

TNF Pharmaceuticals, Inc.

https://www.otcmarkets.com/market-activity/corporate-actions

roxandbonz

roxandbonz 7 월 전

Not sure ,but at 1.14 it’s buying time.

leifsmith

leifsmith 7 월 전

New Name: TNF Pharmaceuticals, Inc. — PR this morning

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. — JULY 22, 2024 9:00AM EDT

* New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system

* Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies

* TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024

https://ir.tnfpharma.com/news-events/press-releases/detail/60/mymd-pharmaceuticals-announces-corporate-rebranding-to-new

This name change makes sense - someone at the company is thinking ...

leifsmith

leifsmith 7 월 전

Interesting PR of 6/17/24: New President and Chief Medical Officer; and new board member

Although there are reasons to doubt the integrity of this company it is possible that this press release means something.

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

https://www.morningstar.com/news/business-wire/20240617357457/mymd-pharmaceuticals-appoints-accomplished-biopharmaceutical-leader-and-current-board-member-mitchell-glass-md-as-president-and-chief-medical-officer

No matter what has failed to happen it is hard to hide the importance of a molecule that can selectively and beneficially regulate TNF-alpha. Ray Blanco was and is right about the science.

SeanVan

SeanVan 7 월 전

Gentlemen!
Can some one please start a class action on this company MYMD.
They reduced 30:1 to 16.6M and now they want to dilute it by increasing up to 250M shares.
All these 3 years, the expenses to this company were negligible. They manipulated stock & accumulated over $100M.

Lets file a Class action law suit on MYMD. The companies that are sincere are having law suits, but this fradulennt company with hight corrupt manipulators must not let go.. This is their 4th company with same kind of fraud.

Check online on APPLE/GOOGLE class action suits and follow same on this ASAP.

critical_perspective

critical_perspective 8 월 전

So now Chapman has jumped ship? The writing was already on the wall. If the research/progress on mymd-1 was/is so promising, then why leave? Chapman's "leadership" was suspect when he became involved with MIRA and TELO. Even with the new 'well-qualified outsider' and new President/CMO Mitchell Glass, I wonder if this is yet another one of Williams' revolving door ploys, replete with smoke and mirrors? Time will tell, but I don't think this bodes well for investors interested in the scientific (and marketable) promise of the company!

tw0122

tw0122 9 월 전

Boom boom pump to $3s dump to $2s

leifsmith

leifsmith 9 월 전

MyMD Pharmaceuticals Secures Strategic Investments, May 21 2024 - 9:00AM

Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front

https://ih.advfn.com/stock-market/NASDAQ/mymd-pharmaceuticals-MYMD/stock-news/93897525/mymd-pharmaceuticals-secures-strategic-investments

deast

deast 9 월 전

As of March 30, 2024 Mirae Asset Global Investment Ltd. holds 875,933 shares (40%) of MYMD? This was posted on another board. Anyone know if this is true?

critical_perspective

critical_perspective 10 월 전

Leif, I think abandonment is an appropriate term. I think the actions of MYMD's (now former) employee Adam Kaplin -- and the company's silence in the 8K -- speaks volumes. When will Chapman jump ship? Is the company's behavior ---which appears full of impropriety -- "just" negligent... or is it criminal? Whatever it is, it certainly is questionable!

deast

deast 10 월 전

8K filed by MYMD April 15, 2024, Adam Kaplan, Chief Scientific Officer resigned.

leifsmith

leifsmith 10 월 전

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug

https://www.biospace.com/article/releases/telomir-pharmaceuticals-unveils-compelling-pre-clinical-data-on-age-reversal-drug-telomir-1-at-national-press-club-event-in-washington-d-c-/

Question: Is Telomir-1 the successor of MYMD-1, discovered by the same people, who are now running Telomir Pharmaceuticals?

Have MYMD investors been totally abandoned while the best discoveries have been homed in a new company?

An unpleasant question to ask. I hope to be proven wrong.

SeanVan

SeanVan 10 월 전

I have been monitoring the pattern of MYMD stocks performance for the past 3 years.... They have bear group/Black pool internal group under Chairman Silverman who does reduce the stock during all good news intentionally. They dont want the fruits to go to investors buy all of their internal known group of people. Whatever happened reflects 100% manipulation like "star scientific" & Rock creek Pharma repetition.

SeanVan

SeanVan 10 월 전

My understannding is that: The 62M stocks reduced to 2.1M and now they want to add/dilute this again upto 62M stocks (12M Common & 50M Preferred Stock) in future by selling to various investors. Its all BIG manipulation.

critical_perspective

critical_perspective 10 월 전

I think it's more smoke and mirrors. (Hope I'm wrong). They sure do a great job of creating the impression they are serious... too much flash 'n fluff... However, we need something concrete other than promises, allusions, and illusions. Completed studies with attendant full reports noting clear & significant findings which either lead to partnerships or to market would help!!

leifsmith

leifsmith 10 월 전

From the 8-K just filed: https://ir.mymd.com/sec-filings/all-sec-filings##document-1028-0001493152-24-013870-1

Bio of Dr. Mitchell Glass (from https://www.medproinvestors.com/team; out of date probably)

Dr. Mitchell Glass is a 25 year veteran of the pharmaceutical industry.
His experience includes senior positions at top ten pharmaceutical companies,
as well as investment in and management of start-ups and biotechs.

After seven years of research, teaching and patient care at the University of Pennsylvania, Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission of the antileukotriene ACCOLATE®. From 1995 to 1996, Dr. Glass was Vice President and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI1067 and was a member of the IPO team. Dr. Glass later joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and currently serves as Executive VP R&D and Chief Medical Officer of Invion Limited. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.

***

I have no idea what any of this 8-K signifies. Maybe tells us some preferred stock can be converted to common on terms specified in subsidiary documents.

critical_perspective

critical_perspective 10 월 전

The primary target for Telomir -- age reversal -- just so happens to align with MYMD's primary target of sarcopenia. Coincidence? I haven't been able to see the actual makeup of Telomir-1 but, like you, I suspect its development is directly linked to the research done for MYMD-1. Why haven't the full results from the sarcopenia study (which ended early June 2023) been published yet? The Annual Report just came out the other day and it does not inspire confidence. Actually, from what I can make of it, it looks quite disappointing... especially with the departure of key individuals. In addition, the lack of communication from the company is disturbing, and in light of everything else, rather alarming.

For those of us who were invested in Williams' previous ventures (i.e. Star Scientific, Rock Creek), this behavior of questionable actions (to say the least) unfortunately appears to be his M.O. He found a compelling means of raising significant capital and then leaving investors dry. I don't have a good feeling about any of it. It is indeed very unfortunate, because the product(s) and the research behind them were truly promising and significant!

leifsmith

leifsmith 11 월 전

Previous msg posted twice. No idea why.

leifsmith

leifsmith 11 월 전

I've noticed that migration. I wonder if the Telomir drug is a direct descendent of MYMD-1. If so, it seems that it should have been kept in MYMD for the benefit of MYMD's investors. Is it the case that they came up with something of extraordinary potential and decided to move it out of MYMD, abandoning the investors there, and put it into a new company to benefit a new group of investors? I hope this is not what's going on, but in the absence of communication from the company we can have no idea.

Monksdream

Monksdream 11 월 전

Regis999

Regis999 11 월 전

Do you know if people on this board were involved in this Scheme?
Notice how they have disappeared !!!!

"The day one of Reverse merger of MYMD with AKERS, the MYMD stock started plummeting. If you carefully monitor the trends of MYMD Stock fluctuations its always down whether you see positive news or not. This continuous manipulation is for a reason... probably bankrupt MYMD and sell this company to a Big pharma for a few Billions. Jonnie did same with Star Scientific & Rock Creek pharma. He ditched millions of sincere investors. I clearly see that he will do one more reverse split to keep the investors away and bankrupt and then sell the company for a great price as it has cleared Phase-2."

SeanVan

SeanVan 11 월 전

The day one of Reverse merger of MYMD with AKERS, the MYMD stock started plummeting. If you carefully monitor the trends of MYMD Stock fluctuations its always down whether you see positive news or not. This continuous manipulation is for a reason... probably bankrupt MYMD and sell this company to a Big pharma for a few Billions. Jonnie did same with Star Scientific & Rock Creek pharma. He ditched millions of sincere investors. I clearly see that he will do one more reverse split to keep the investors away and bankrupt and then sell the company for a great price as it has cleared Phase-2...

critical_perspective

critical_perspective 11 월 전

Anyone care to share their thoughts on this? It appears that Chris Chapman and Adam Kaplin have key roles in two more of Jonnie's new ventures: MIRA Pharma and Telomir Pharma. Until very recently Adam Kaplin was President and Chief Scientific Officer of MIRA Pharmaceuticals while Chapman was their CEO & Chairman of the Board. Now they are both gone from MIRA (or have greatly reduced roles) and have taken up new positions at Telomir

My question is: what about MYMD?? How can anyone expect to have any confidence in them or in the company when they do something like this?? Shouldn't they be devoting their time and energies to advancing the research and interests of MYMD?Is this even ethical? No wonder why the share value has been and is plummeting! Is this just another one of Jonnie's schemes? What do you all think?

Regis999

Regis999 11 월 전

"Hopefully, Williams gets it right this time." Not this time................

Regis999

Regis999 11 월 전

30 for 1 Reverse Split is not a positive event. All investors are under water.

deast

deast 12 월 전

Please remain under your rock and refrain from your annoying nonsense.

Regis999

Regis999 12 월 전

Williams is one of the worse business men on the planet.

Monksdream

Monksdream 12 월 전

MYMD new 52 week low

Regis999

Regis999 1 년 전

Pathetic !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Williams strikes again

Renee

Renee 1 년 전

MYMD: effective Feb. 15,2024 a one for 30 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

SeanVan

SeanVan 1 년 전

check this out.. about MyMD founder

https://www.newsweek.com/2014/01/24/funny-money-man-behind-mcdonnells-fall-245100.html

SeanVan

SeanVan 1 년 전

I have been telling in this board to all since many months that.... The Chairman of the Board Josh Silverman came from AKERS who is expert inn manipulation of the stocks... Now 30:1 reverse split will happen tomorrow, which reduces to shares 2,091,638. Important to note that, they already got approval from NASDAQ to add upto 16M new stocks if needed. This so called manipulators MyMD Founder Johnnie W, & Silverman add those remaining shares in short time which dilutes the value by saying Phase 3 purposes. This company is living on all frauds. What do you say?

deast

deast 1 년 전

Reverse split. 30 to 1.

SeanVan

SeanVan 1 년 전

Nasdaq Delisting of MYMD Notice as expected by Many sincere investors:
.
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317802932&type=HTML&symbol=MYMD&cdn=d11231e10863bcbb58b0c4d4615e2222&companyName=MyMD+Pharmaceuticals+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2023-10-13

deast

deast 1 년 전

I hope they find a partner because the hacks at the SEC might not be able to distinguish a naked short from a flasher. Just my humble opinion.

B and B

B and B 1 년 전

Not until the sec sends the naked short to prison or the company finds a partner. It’s a zero or 100+ dollar stock Make your bet at least I know my downside

Regis999

Regis999 1 년 전

New low at $ .165 on HUGE volume Will the selling ever end?

leifsmith

leifsmith 1 년 전

Canadian patent 3013634 granted

Abstract: "In one aspect, a method of increasing hair growth includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of improving the appearance of hair includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor."

isomyosmine (MYMD-1) is interestingly versatile.

Near the close the price went as high as 0.21 on over 3,200,000 shares, then collapsed to 0.17 on much lower volume, closing at 0.203. After hours 0.18 seems to be popular. Hair raising, if you care. I don't much. This announcement means little, far as I can tell.

Regis999

Regis999 1 년 전

New 52 week low on huge volume--down trend continues

leifsmith

leifsmith 1 년 전

I don't know about Ray Blanco's current list. Read something by him many months ago. He was right then, and still right now about the science. But badly wrong about a good time to buy.

MyMD Pharmaceuticals

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관